Ready to untap the future of bioconjugates in oncology and beyond?
This is where the next wave begins..
The 5th Novel Conjugates Summit brings clarity to the fast-moving bioconjugate space, with three days dedicated to spotlighting the most exciting advances in novel targeting formats and payloads so you can return to your team equipped with a breadth of insight into the current approaches being explored.
Unmissable Event Highlights
Engineering Novel Targeting Formats
Explore how multispecifics, antibody fragments, and peptides are being engineered to enhance tumor penetration, unlock previously inaccessible targets, and enable more selective delivery of therapeutic payloads. Hear fresh perspectives from innovators advancing the next wave of targeting strategies.
Innovating Payload Design to Overcome Resistance
Learn how emerging payload classes such as degraders, oligonucletides and immune stimulants are being harnessed to overcome resistance mechanisms and expand conjugate efficacy beyond traditional cytotoxics.
Investor & Pharma Partnering Panel
Hear directly from pharma search & evaluation teams and leading investors on what drives strategic interest in novel conjugate platforms, and how emerging biotechs can position themselves for collaboration or acquisition.
Designing Smarter Linker & Payload Strategies
Join our deep-dive workshop on how linker chemistry, payload potency and targeting format interact to influence conjugate performance.
Building Collaborative Bridges Across Modalities
Join cross-functional discussions between antibody, peptide and oligonucleotide experts to uncover how lessons learned in each modality can accelerate innovation in new conjugate designs and delivery strategies.
Attending Companies Include